Cellares raised $257 million in a Series D round to accelerate global expansion of its clinical‑stage cell therapy manufacturing services and prepare for a 2027 IPO. The funding will support commercial launch of its automated cell therapy production technology and scale contract manufacturing operations. In parallel, Automata closed a $45 million Series C and announced a partnership with Beckman Coulter Life Sciences, underscoring sustained investor interest in lab automation and scalable manufacturing for biologics. Investors and strategic partners are funneling capital into automation and distributed manufacturing to reduce costs and shorten time to patient for cell and gene therapies. The combined financing and partnerships suggest a market shift: developers now prioritize manufacturing solutions alongside discovery platforms to enable clinical and commercial supply.